A G Pernet
Overview
Explore the profile of A G Pernet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alcorn K, Nary G, Pernet A, Surchio J, Weiner J
J Int Assoc Physicians AIDS Care
. 1996 Apr;
2(4):48-51.
PMID: 11363519
No abstract available.
2.
Fuhr U, Strobl G, Manaut F, Anders E, Sorgel F, Chu D, et al.
Mol Pharmacol
. 1993 Feb;
43(2):191-9.
PMID: 8429824
The inhibitory effect of 44 quinolone antibacterials and derivatives (common structure, 4-oxoquinoline-3-carboxylic acid) on cytochrome P450 isoform CYP1A2 activity was tested using human liver microsomes and caffeine 3-demethylation as a...
3.
Granneman G, Carpentier P, Morrison P, Pernet A
Antimicrob Agents Chemother
. 1992 Feb;
36(2):378-86.
PMID: 1318680
The multiple-dose pharmacokinetics and tolerance of temafloxacin, a new fluoroquinolone antibacterial agent, were evaluated in healthy volunteers. Temafloxacin was found to be well tolerated when administered orally every 12 h...
4.
Krasula R, Pernet A
Am J Med
. 1991 Dec;
91(6A):38S-41S.
PMID: 1662894
This article summarizes animal studies conducted to determine the toxic and mutagenic potential of temafloxacin. The four target tissues of potential concern with fluoroquinolone use are the kidney, the eye,...
5.
Pernet A
Am J Med
. 1991 Dec;
91(6A):162S-165S.
PMID: 1662888
During the Phase I, II, and III clinical development program, temafloxacin has demonstrated an excellent safety profile, with reported overall rates of adverse events comparable to quinolone and nonquinolone reference...
6.
Norrby S, Pernet A
J Antimicrob Chemother
. 1991 Dec;
28 Suppl C:111-9.
PMID: 1664824
The safety of temafloxacin was evaluated in 753 subjects in phase I trials and in 2602 patients included in phase II and III studies. Comparative treatment was given to 153...
7.
Granneman G, Carpentier P, Morrison P, Pernet A
Antimicrob Agents Chemother
. 1991 Mar;
35(3):436-41.
PMID: 2039194
Temafloxacin (A-63004) is a new quinolone antibacterial agent with a broad spectrum of activity against gram-positive and gram-negative aerobes and anaerobes. The pharmacokinetics and metabolism of temafloxacin were determined in...
8.
Chu D, NORDEEN C, Hardy D, SWANSON R, Giardina W, Pernet A, et al.
J Med Chem
. 1991 Jan;
34(1):168-74.
PMID: 1846917
Temafloxacin hydrochloride [(+/-)-7-(3-methylpiperazin-1-yl)-6-fluoro-1-(2,4-difluorophenyl)- 1,4-dihydro- 4-oxoquinoline-3-carboxylic acid hydrochloride] is a potent member of the 4-pyridone-3-carboxylic acid class of antibacterial agents and is currently under clinical development as a broad-spectrum antimicrobial agent....
9.
Chu D, Lico I, SWANSON R, Marsh K, Plattner J, Pernet A
Drugs Exp Clin Res
. 1990 Jan;
16(9):435-43.
PMID: 2100244
Tosufloxacin (5, A-61827 tosylate or T-3262) is currently under product development by both Abbott Laboratories and Toyama Chemical Co. Its registration as antibacterial agent has been approved in Japan. It...
10.
Chu D, Lico I, Claiborne A, Plattner J, Pernet A
Drugs Exp Clin Res
. 1990 Jan;
16(5):215-24.
PMID: 1964116
Very little is known about the structure-activity relationship of quinolone antibacterials at the 2-position. Because of the loss of biological activity with 2-methyl and 2-hydroxyl substitution, modifications at C-2 were...